Skip to Content

Understanding Mechanisms Behind Acquired Resistance to Immunotherapy in Metastatic Renal Cell Carcinoma

In this study, the aim was to explore the genetic and transcriptomic markers associated with acquired resistance (ARX) to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC). Listen to Eddy Saad about the mechanisms behind acquired resistance in this MEDtalk from ASCO GU 2024.

Eddy Saad

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top